Antiviral agent 5 is a crucial intermediate utilized in the development of antiviral agents that specifically target 3C and 3CL proteases, which includes the SARS-CoV-2 M pro enzyme.
(E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) that may be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner. It enhances the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, increasing survival time.
L-I-OddU, a potent and selective anti-Epstein-Barr virus (EBV) agent, is a L-5'-halo-dioxolane nucleoside analogue. It demonstrates antiviral activity by effectively suppressing replicative EBV DNA and viral protein synthesis [1] [2]. With an EC 50 value of 0.03 μM, L-I-OddU exhibits high potency against EBV while maintaining low cytotoxicity, as indicated by its CC 50 value of 1000 nM.